Vyome Holdings, Inc.

Vyome Holdings, Inc.

HIND

Get informed when a big investor buys or sells

+ Follow
Market Cap$14.74M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Vyome Holdings, Inc.Vyome Holdings, Inc.-0.1--162%-2-
$3.50

Target Price by Analysts

74.1% upsideVyome Holdings Target Price DetailsTarget Price
$2.07

Current Fair Value

3.1% upside

Undervalued by 3.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$14.74 Million
Enterprise Value$6.89 Million
Dividend Yield$- (-)
Earnings per Share$-4.75
Beta1.51
Outstanding Shares7,018,528

Return

Return on Equity-161.66%ROE
Return on Assets-106.56%
Return on Invested Capital-134.48%

Valuation & Multiples

P/E Ratio-0.07P/E Ratio
PEG0.09PEG
Price to Sales-2.01Price to Sales
Price to Book Ratio2.01Price to Book Ratio
Enterprise Value to Revenue-3.48
Enterprise Value to EBIT-0.7
Enterprise Value to Net Income-1
Total Debt to Enterprise0.01
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.19
Average shareholder expectation
Revenue Estimate
$26,955
Average shareholder expectation

Next Earnings Call

Expected Date
November 13, 2026
EPS Estimate
$-0.16
Average shareholder expectation
Revenue Estimate
$24,111
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %1.97%▲ 0.41%
Total Invested$296,510▲ 49.55%
Investors Holding12▲ 3.00%

ESG Score

No data

About Vyome Holdings, Inc.

18 employees
CEO: Venkateswarlu Nelabhotla

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disor...